AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04730440 — intervention group
Intervention type: OTHER
Intervention: AD-TAR
Description: Intervention description: 12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using a rehabilitation program named Training of Affect Recognition (TAR).
Study NCT04730440 — intervention group
Intervention type: OTHER
Intervention: AD-Cognitive Stimulation
Description: Intervention description: 12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using classic cognitive stimulation workshops.
Study NCT00654667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, no active drug, take 5 capsules by mouth daily for one month
Study NCT00654667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Study NCT03674944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss (BWL) + Emotion Regulation (ER)
Description: The BWL + ER program will teach Dialectical Behavior Therapy (DBT) skills (dialectical abstinence, emotion regulation skills, mindfulness, and distress tolerance) to the adolescent and parent group sessions. Parents are expected to model skill usage and DBT language with their teen to reinforce the skills at home. Adolescents and parents will track emotions and DBT skills used in diary cards which will be provided. Emotion-Focused Parent Training (EFPT) will be provided to the parents at each session to train the parent to support the adolescent in processing emotions, increasing parental emotion self-efficacy, promoting positive parent-adolescent relationships, and reducing the need for dysfunctional emotion regulation behaviors.Behavior coaching will be provided to the adolescent and parent to encourage compliance and review skills after each session (DBT or BWL).
Study NCT03674944 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss (BWL)
Description: All participants will be instructed to consume an energy restricted diet based on initial body weight. Participants will be instructed to record and self-monitor their food intake. The physical activity component will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations will include: self-monitoring, goal setting, managing high-risk situations, and relapse prevention. Parenting skills will be discussed during parent group sessions which will encourage parents to adopt authoritative parenting styles with regard to eating and exercise behaviors. Parents will also learn about behavioral modification principles, including modeling, reinforcement, and operant conditioning. Behavior coaching will be provided to the adolescent and parent after each session to encourage compliance, discuss completed homework, review habit books to praise efforts and give feedback for areas of improvement.
Study NCT03674944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss (BWL)
Description: All participants will be instructed to consume an energy restricted diet based on initial body weight. Participants will be instructed to record and self-monitor their food intake. The physical activity component will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations will include: self-monitoring, goal setting, managing high-risk situations, and relapse prevention. Parenting skills will be discussed during parent group sessions which will encourage parents to adopt authoritative parenting styles with regard to eating and exercise behaviors. Parents will also learn about behavioral modification principles, including modeling, reinforcement, and operant conditioning. Behavior coaching will be provided to the adolescent and parent after each session to encourage compliance, discuss completed homework, review habit books to praise efforts and give feedback for areas of improvement.
Study NCT02632032 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Insulin
Description: Monitoring insulin therapy of campers based on their usual regimen (one of the following):~* premixed insulin in the morning and evening,~* premixed insulin in the morning, regular insulin in the afternoon and premixed insulin in the evening,~* regular insulin in the morning and afternoon, and premixed insulin in the evening.~Education of campers on different aspects of diabetes care:~* monitoring of blood glucose~* injection of insulin~* adaptation of insulin doses according to blood glucose and during exercise~* correction of hypoglycemia~* dietary advice
Study NCT00627263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress reduction treatment (SRT) program
Description: The SRT program is a cognitive behavioral program that consists of 8 group sessions over a period of 10 weeks.
Study NCT00423930 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00423930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00423930 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00423930 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Study NCT04002401 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: A single infusion of CAR-transduced autologous T cells administered intravenously
Study NCT04002401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered intravenously
Study NCT01964508 — intervention group
Intervention type: OTHER
Intervention: Fine needle aspiration
Study NCT01848015 — intervention group
Intervention type: OTHER
Intervention: detection of CTCs
Study NCT03161535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and dietary education
Description: 1. A 12-week regimen of home-based walking exercises, comprising walking at a moderate intensity for 40 min, three times a week, was administered along with weekly exercise counseling. After collecting pretrial measurements, we explained the participants how to perform the exercises, according to an instruction manual for the exercise regimen. The detailed instructions, provided at the hospital clinics, included the determination of activity intensity, demonstration of pulse measurement, criteria for scores of 6-20 on the Borg's rating of perceived exertion (RPE), prevention of exercise-related injuries, and conditions necessitating termination of an exercise session. Participants were instructed that the exercises would be effective only if they reached 60%-80% of the target heart rate, as determined by the Karvonen method, and 13-15 on the RPE.~2. Diet-teaching program (using dietary education booklet).
Study NCT03161535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weekly telephone consultations concerning exercise and diet.
Description: For each participant, we discussed exercise regimen-related issues and diet weekly through the telephone. For instance, we discussed whether participants' exercise fulfilled the prescribed intensity, duration, or frequency and whether the participants experienced any adverse effects.
Study NCT04564417 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: W0180
Description: Participants will receive W0180 in a 21-day cycle.
Study NCT04564417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will receive Pembrolizumab 200 mg flat dose as IV infusion every three weeks (Q3W) in a 21-day cycle.
Study NCT02513563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will be treated with carboplatin (area under the curve 5 (AUC5) will be used to determine the dosage) twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
Study NCT02513563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Participants will be treated with paclitaxel 175 mg/m\^2 twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
Study NCT02513563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: Participants will receive AZD1775 225 mg twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
Study NCT03166917 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D printing implant
Description: 3D printing implants in bone defect
Study NCT03166917 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: autogenous bone grafting
Description: 3D printing implants in bone defect
Study NCT03104881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D exoskeleton type robot
Description: 3 dimension exoskeleton type upper extremity robot
Study NCT03104881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2D end-effector type robot
Description: 2 dimension end-effector type upper extremity robot
Study NCT00976807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Eight week programme of twice-weekly (sixteen sessions) supervised exercise and education sessions. Exercise will include aerobic cardiovascular and upper and lower limb strengthening exercises. Each session will comprise a warm-up period, followed by individualised exercises, and completed with a cool-down, and last approximately 40minutes.~Aerobic exercise will be prescribed based on the results of walking tests and include walking, step-ups, cycling, and strength prescription according to the repetition maximum principle. Patients will complete three sets using this weight.~Furthermore Borg scores will be used within each session to guide and direct exercise intensity. A home exercise programme will also be designed and accompanied by a manual detailing the individual warm-up, exercises and cool-down, and diary sections to record independent activity.~Each session will also include an education session where relevant.
Study NCT04828421 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus and Bifidobacterium lactis
Description: Probiotics
Study NCT04828421 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01969708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aflibercept
Study NCT01969708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Study NCT01075243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Description: Paracetamol 1000mg
Study NCT01075243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 650 mg
Description: Paracetamol 650 mg
Study NCT01075243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01762410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P7170
Description: Patients will receive study drug on a daily basis for twenty-one days according to the dose and schedule specified for a particular cohort of therapy. This 21 day administration will define a treatment cycle. Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, death or withdrawal from the protocol as specified.
Study NCT00691613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alpha
Description: The dosage (60.000 I/U Epoetin alpha) will be diluted in 10 ml of 0.9% sodium chloride solution and injected in a single dose intravenously in the dominant forearm (the non-dominant forearm will be used as ischemic model).
Study NCT00691613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: 0.9% sodium chloride solution as placebo dosage is 10 ml, which will be administered in the same manner as the interventional medicinal product.
Study NCT01591200 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Mesenchymal Stem Cells
Description: High dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
Study NCT01591200 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Mesenchymal Stem Cells
Description: Intermediate dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
Study NCT01591200 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Mesenchymal Stem Cells
Description: Low dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
Study NCT02553213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy
Description: The surgical procedure and aftercare is indicated and performed according to the routine clinical setting of the Hospital. Patients stay 5 days stationary after surgical treatment. They receive a defined easy digestible diet, starting with liquid and mash food.
Study NCT02553213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass
Description: The surgical procedure and aftercare is indicated and performed according to the routine clinical setting of the Hospital. Patients stay 5 days stationary after surgical treatment. They receive a defined easy digestible diet, starting with liquid and mash food.
Study NCT02553213 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Caloric restriction diet
Description: Patients of the control group do not undergo surgical treatment. They undergo a caloric restriction diet for 5 days. This diet is adapted to the postoperative diet of the patients included in the two other groups.
Study NCT02553213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: easy digestible diet
Study NCT00788216 — intervention group
Intervention type: OTHER
Intervention: Discussion & scoring of health states related to the treatment of cervical cancer
Description: Subjects will be interviewed using the visual analog score and time trade off methods.
Study NCT02923973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound cervical length screening
Description: Serial transvaginal ultrasound cervical length scan every week from 16 to 24 weeks
Study NCT01171859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline + Tauroursodeoxycholic acid
Description: doxycycline 100 mg twice a day for 12 months; tauroursodeoxycholic acid 250 mg three times a day for 12 months
Study NCT02028806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
Study NCT01849510 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated 12x3 Gy + integrated boost 12x4 Gy
Description: hypofractionated, homogeneous radiation (12x3 Gy) with simultaneously administrated, integrated boost (12x4 Gy) mediated by IGRT \& hfSRT
Study NCT01849510 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: hypofractionated 10x3 Gy
Description: hypofractionated, homogeneous radiation (10x3 Gy)
Study NCT04757506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: opioid receptor antagonist
Study NCT04757506 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04299373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol: Oral administration
Description: Patients who plan to undergo bariatric surgery will consume a controlled dose of alcohol orally.
Study NCT04299373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol: Intravenous administration
Description: Patients who plan to undergo bariatric surgery will be infused with alcohol intravenously.
Study NCT00566436 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote endarterectomy of the superficial femoral artery
Description: Exposure of the common femoral, superficial femoral and profunda femoral artery through a single groin incision. Arteriotomy in the proximal SFA followed by dissection of the intima core beyond the occluded segment using the Vollmar ringstripper. The ringstripper is exchanged for a Mollring cutter all under fluoroscopic guidance. With the Mollring Cutter transection of intima core is carried out, remote from the site of entry. After removal of the intima core the transection zone is secured with an aSpire stent after balloon angioplasty. A completion arteriography will verify a patent artery, and embolectomy can be performed when necessary. As indicated a common femoral artery and profundaplasty can be performed and the arteriotomy may be closed with or without patch.
Study NCT00566436 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprageniculate femoropopliteal bypass
Description: Groin and suprageniculate incision, venous (Saphenous vein) or PTFE graft with end to side anastomoses. If the saphenous vein is truly applicable for grafting will ultimately be an intra-operative decision (despite pre-operative venous mapping)
Study NCT01091064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Randomization early depart
Description: Patients will be randomized to either an early depart or for being seen by a physician.
Study NCT01169103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH)
Description: Initial rhGH dose 0.4mg administered by subcutaneous injection daily. Dose will be increased to 0.6 mg after one week and then increased to 0.8mg after two weeks.
Study NCT01169103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by daily subcutaneous injections. Sham increases will be used.
Study NCT02468817 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Exercise
Description: 2 (two) 1-hour of vigorous exercise bouts under different thermal conditions
Study NCT02468817 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnitude of Ca loss during Exercise at 26 degrees Celcius
Description: Blood samples at 15-min intervals starting 15 min before exercise and ending 60 min after exercise
Study NCT01271777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFT505 80mg
Description: hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast
Study NCT01271777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: hard gelatin capsules, oral administration, 4 capsules per day before breakfast
Study NCT03309020 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Cataract surgery and aqueous humor sampling.
Study NCT03309020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Cataract surgery and aqueous humor sampling.
Study NCT04002401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered according to package insert
Study NCT04002401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered according to package insert
Study NCT04642872 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant BIT
Description: Not use of unaffected hand containment. Both hand are use to improve the bimanual coordination
Study NCT04642872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant BIT
Description: Not use of unaffected hand containment. Both hand are use to improve the bimanual coordination
Study NCT03983733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: To carry out an interventional dietary study using standardised meals to predict an individual's metabolic response to certain foods, using their gut microbiome, metabolic profile, and other measurable characteristics such as weight, sleep and exercise.
Study NCT03454295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Participants will be asked to reflect on their caregiving experience and specifically, when the receipt of a supportive intervention that addresses existential distress would have been most appropriate and well received.
Study NCT03454295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaning-Centered Psychotherapy for Cancer Caregivers / MCP-C
Description: MCP-C is structured as a 7-session (1-hour weekly or biweekly sessions) individual intervention that utilizes a mixture of didactics, discussion and experiential exercises that focus around particular themes related to meaning and cancer caregiving
Study NCT03454295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care / EUC
Description: The enhancement to usual care in this study involves the inclusion of screening and targeted referral components as suggested by Reynolds et al. \[79\]. Research study assistants conducting the screening and providing feedback and referrals will be trained in the NCCN guidelines for distress management and will discuss the screening results and associated recommendations with the study PI (NCCN) \[63\]. As of November, 2017, ICs of patients seen in the Neurology Service at MSKCC are not consistently screened for distress and offered targeted referrals. Participants randomized to EUC will receive feedback about their level of distress (based on the Distress Thermometer administered at screening) after randomization. Within a week of randomization, and post-baseline, the study RSA will send EUC participants appropriate targeted referrals based on levels of distress and problem areas endorsed.
Study NCT01931540 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Three times a week, for four months.
Study NCT06156020 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic endonasal surgery
Description: Endoscopic endonasal transsphenoidal approach for resection of pituitary adenomas